The latest from Hartepicar Biosciences, plus how independent analysts rate our science, our pipeline, and our approach to pricing.
The study enrolled 412 participants across 14 sites. Topline results are expected in the first half of 2027. Nicole Mascone, Senior Scientific Researcher on the Skin Longevity team, said the milestone reflects years of work on how the dermal matrix changes with age.
The company explained why its record-setting therapies will launch at premium prices, citing the cost of discovery, manufacturing quality, and long-term outcome studies.
Proceeds will fund a larger peptide manufacturing suite, late-stage trials for HPC-101, and the advance of HPC-204 into its next phase.
The talk covered how fibroblast signaling shifts with age and what that means for the next generation of renewal therapies.
The new suite triples production capacity and adds in-house quality testing, supporting Chief Scientific Officer Markus Webb's goal of controlling quality from bench to batch.
Chief Medical Officer Julian Prewitt, M.D., will work with the board to review safety data across all active trials.
The designation is intended to speed development of the Accelerated Wound Matrix for patients with limited treatment options.
Media inquiries: media@hartepicar.com
Scores out of five from three independent review groups.
All rating groups and scores on this page are fictional sample data created for a training exercise. They do not come from any real rating organization.
| Program | Stage | Efficacy signal | Safety profile | Analyst outlook |
|---|---|---|---|---|
| HPC-101 Dermal Renewal Peptide Complex | Phase II | Strong | Favorable | Positive |
| HPC-204 Accelerated Wound Matrix | Phase I | Early positive | Favorable | Cautiously positive |
| HPC-310 Cellular Longevity Modulator | Preclinical | Not yet assessed | Not yet assessed | Neutral |